HUMAN CHORIONIC GONADOTROPIN (HCG)
- Known as:
- HUMAN CHORIONIC GONADOTROPIN (HCG)
- Catalog number:
- 189-11
- Product Quantity:
- 1000 units
- Category:
- -
- Supplier:
- LeeBio
- Gene target:
- HUMAN CHORIONIC GONADOTROPIN (HCG)
Related genes to: HUMAN CHORIONIC GONADOTROPIN (HCG)
- Gene:
- CGA NIH gene
- Name:
- glycoprotein hormones, alpha polypeptide
- Previous symbol:
- -
- Synonyms:
- HCG, GPHa, GPHA1, FSHA, LHA, TSHA
- Chromosome:
- 6q14.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2015-08-25
- Gene:
- CGB5 NIH gene
- Name:
- chorionic gonadotropin subunit beta 5
- Previous symbol:
- -
- Synonyms:
- HCG
- Chromosome:
- 19q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 2001-12-05
- Date modifiied:
- 2018-04-23
- Gene:
- DNAJB3 NIH gene
- Name:
- DnaJ heat shock protein family (Hsp40) member B3
- Previous symbol:
- -
- Synonyms:
- HCG3
- Chromosome:
- 2q37.1
- Locus Type:
- unknown
- Date approved:
- 2008-06-17
- Date modifiied:
- 2016-10-05
- Gene:
- ETF1P1 NIH gene
- Name:
- eukaryotic translation termination factor 1 pseudogene 1
- Previous symbol:
- SUP45L2
- Synonyms:
- HCGVII
- Chromosome:
- 6p22.1
- Locus Type:
- pseudogene
- Date approved:
- 1999-08-12
- Date modifiied:
- 2016-10-05
- Gene:
- GIHCG NIH gene
- Name:
- GIHCG inhibitor of miR-200b/200a/429 expression
- Previous symbol:
- -
- Synonyms:
- lncRNA-GIHCG
- Chromosome:
- 12q14.1
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2018-07-25
- Date modifiied:
- 2019-01-25
Related products to: HUMAN CHORIONIC GONADOTROPIN (HCG)
Related articles to: HUMAN CHORIONIC GONADOTROPIN (HCG)
- Achieving potent immunosuppression while minimizing off-target and exposure-limiting toxicities remains a key goal in organ transplantation. JAK3 is a nonredundant mediator of γc-cytokine signaling and an attractive target for lymphocyte-restricted immunomodulation; however, existing JAK3 inhibitors may show incomplete isoform selectivity and/or uncertain durability of cellular pathway suppression. We therefore developed a novel JAK3 inhibitor, J1f, and performed a preclinical evaluation of its selectivity and immunosuppressive efficacy. - Source: PubMed
Publication date: 2026/05/15
Yu ShengnanFeng XianjingZhong JiayingJin ZeqiangZheng QishengLiu BingLi JieZhang JieWang WenjunSu ZhaojieHe LinhongXia Junjie - Previous studies indicated that cell-free RNA (cfRNA) in spent embryo medium (SEM) may serve as a noninvasive biomarker for evaluating embryonic development. However, its stage-specific expression patterns and functional dynamics during preimplantation embryos are still unclear. In view of this, this study performed transcriptome sequencing on cfRNAs from follicular fluid (FF) and SEM at different developmental stages. This result showed that the number of identified cfRNAs showed a trend of decreasing from follicular to cleavage stage, then increasing through blastocyst stage. The proportion of low abundance genes of protein coding RNA (mRNA) and long noncoding RNA (lncRNA) in FF and spent cleavage medium (SCM) was relatively high (0 < FPKM ≤ 10). The proportion of low abundance genes of mRNA and lncRNA in spent blastocyst medium (SBM) was lower than that of high abundance genes (FPKM > 10). The cfRNAs of differentially expressed were detected in FF, including ribosomal proteins and genes involved in protein translation. The genes regulating protein kinase activity were significantly enriched in SCM. Cellular signal transduction, energy metabolism, immunity, RNA transcription, and splicing genes were significantly enriched in SBM. Further studies revealed that immune genes (JAK3, STAT6, DOCK8, CD74) in SBM were closely related to embryo quality, and the expression level of immune genes in high-grade SBM (hSBM) was significantly (p < 0.05) higher than that of low-grade SBM. The Wnt/β-catenin signaling pathway was found to be associated with hSBM, potentially contributing to blastocyst development through the release of immune factors and activation of immune-related pathways. However, these findings were preliminary. Therefore, this study results provide new insights into the molecular dynamics of preimplantation embryos and the impact of immune responses on embryo quality. - Source: PubMed
Shi HuajuanSheng YuqiZhang ChunnuanPan MinLi LehanJing AihuaCai LingboGe Qinyu - Previous studies have reported that ginger (Zingiber officinale) and its extracts (or components such as gingerols) can alleviate inflammatory bowel disease (IBD). Herein, we report the evaluation of Cedrol (CE), a bioactive compound from ginger, for its therapeutic potential in IBD-an application that, to our knowledge, has not been previously investigated. - Source: PubMed
Publication date: 2026/02/14
Diao HaiyangQin TonghuiZheng YifeiHan LinlinZhao Yuqing - The Janus Kinase 3 (JAK3) germline gain-of-function (GOF) mutation is a rare inborn error of immunity, first reported in 2020, characterized by lymphopenia and chronic NK-cell proliferation. However, its role in autoimmunity remains unclear, and no direct association with hyper-IgE syndrome (HIES) has been established. In this study, we describe a patient presenting with HIES, myositis, lymphopenia, and autoimmune hypothyroidism. Whole-exome sequencing identified a novel compound heterozygous JAK3 mutation (c.2524_2525delinsTT and c.2805G > C), predicted to be deleterious. Flow cytometry and RNA sequencing of peripheral blood mononuclear cells revealed a significant reduction in T cells and NK cells, particularly naïve CD4 T cells, accompanied by a marked imbalance in T cell subsets. This led to constitutive activation of JAK1 and JAK3, along with increased STAT3 and STAT5 phosphorylation. Tofacitinib treatment significantly improved the patient's symptoms. Our findings expand the clinical spectrum of JAK3-associated immune dysregulation, linking it for the first time to HIES and multiple autoimmune manifestations. Furthermore, this study suggests that tofacitinib may be a potential therapeutic option for JAK3 signaling-associated immune dysregulation. - Source: PubMed
Publication date: 2026/05/09
Pei YuxinJin BeiAbasi ReyilaCheng ChengZhuang HongjieZeng ShuhanJiang MengjiePei HeyingJiang Xiaoyun - To investigate the clinicopathological and molecular features of meningioma, and to analyze the characteristic molecular changes in high-grade meningioma (WHO grades 2-3). A total of 139 meningioma specimens from 134 patients treated at Xuanwu Hospital, Capital Medical University from 2015 to 2020 were collected, including 49, 62 and 28 samples of WHO grades 1, 2 and 3 meningiomas, respectively. Clinical data and pathological diagnoses were reviewed. Next-generation sequencing (NGS) was conducted to analyze the associations of molecular biomarkers with clinicopathological features and prognosis. Among the 134 patients, 59 patients (44.0%) were male, and 75 (56.0%) were female, age 57 (49, 66) years old. The most common genetic alteration was NF2 mutation (43.2%, 60/139). In non-NF2 mutated meningiomas, the hotspot genes of detectable mutations were AKT1 (13.7%, 19/139), TRAF7 (9.4%, 13/139), KLF4 (5.7%, 8/139), SMO (5.7%, 8/139), and PIK3CA (1.4%, 2/139). Twelve of the 13 cases TRAF7 alterations co-occurred with other genetic changes. Some molecular alterations were associated with histological subtypes. For instance, NF2 mutations were most frequently detected in psammomatous meningiomas (2/2) and fibrous meningiomas (8/9), while all secretory meningiomas harbored KLF4 mutations (6/6). Some molecular alterations were associated with tumor grade and prognosis. JAK3 mutations (4.3%, 6/139), TERT promoter mutations (3.6%, 5/139), and homozygous deletion of CDKN2A/B (4.3%, 6/139) were exclusively found in high-grade meningiomas. TERT promoter mutations and CDKN2A/B homozygous deletion (versus normal) were both independently associated with poorer prognosis (<0.001 for both). JAK3 mutation was also associated with shorter overall survivals (=0.031). NF2 is the most frequently mutated gene in meningiomas. TERT promoter mutations and CDKN2A/B homozygous deletion occur exclusively in high-grade meningiomas, link to unfavorable prognosis, and can serve as independent diagnostic markers for WHO grade 3 meningioma. JAK3 mutation seems also to be associated with high-grade meningiomas and shorter survivals. - Source: PubMed
Gao MWang L MXiong Y LZhao L HHu Z LZhang X WTeng L H